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VARIOUS authors have demonstrated that the growth of a tumour can be
retarded by pre-treatment ofthe host before grafting the tumour, by either irradi-
ated tumour cells (Glynn et al., 1963) or by the adjuvants, BCG (Amiel, 1967;
Balner, Old and Clarke, 1962; Biozzi, et al., 1959; Halpern et al., 1959) and
Corynebacterium parvum (Halpern et al., 1964; Halpern et al., 1966; Woodruff
and Boak, 1966). In these instances, the therapy was begun before the onset
of growth of the tumour.
In the present state of our knowledge of the antigens of human tumour cells,
one cannot envisage the application of the immunotherapy of cancer in a preven-
tive form, that is, before the onset of the disease. On the other hand, one can
see the possibility of applying the technique in a curative role. For this reason
we wish to know if it can be effective when applied after the development of the
neoplasm, that is, when the animal is already carrying the tumour cell antigens.
We have already shown that this is a possibility (Mathe, 1968) and described some
ofthe conditions under which it was effective.
We are now making a detailed study of these conditions by a series of experi-
ments carried out on transplantable leukaemia, on a virus-induced leukaemia and
on spontaneous leukaemia. The present paper is concerned with the results
of experiments on a transplantable leukaemia.
MATERIALS AND METHODS
The L1210 leukaemia maintained in DBA/2 mice, was used as a graftable
leukaemia. This was transplanted into (C57BL/6 x DBA/2)F1 mice aged three
months.
Experiment 1: A Comparison ofthe Effect upon Leukaemia Produced by the Injection
of 104 Cells, of Single or Repeated Injections of Various Adjuvants, and Irradiated
Leukaemic Cells Given After the Graft of the Leukaemia
Two hundred and eighteen mice received 104 L1210 leukaemic tumour cells,
by subcutaneous injection; they were then divided at random into 10 groups of
20 animals and one group of 18. The first group acted as controls. Groups 2 and
3 were treated with living BCG*: group 2, by a single intravenous injection of
1 mg. 24 hours after the graft; group 3, by 5 injections of 1 mg. every fourth day,
beginning 24 hours after the graft. Groups 4 and 5 were treated by Bordetella
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pertussis*: 1 mg. intraperitoneally as a single injection (group 4), or repeated
5 times at 4 days intervals (group 5). Groups 6 and 7 were treated by Coryne-
bacterium parvum*: 1 mg. intraperitoneally, either as a single injection (group 6),
or repeated 5 times at 4 day intervals (group 7). Groups 8 and 9 were treated by
Mycobacterium cheilonit: 1 mg. intraperitoneally as a single dose (group 8), or
repeated 5 times at 4 day intervals (group 9). Groups 10 and 11 were treated by
injection of 107 L1210 leukaemic cells that had been irradiated with 15,000 rads,
either as a single injection (group 10), or repeated 5 times at 4 day intervals
(group 11); the conditions of the irradiation in vitro were as follows: a suspension
ofcells was prepared containing 5 x 107 cells per mm.3; the suspension was divided
into 4 5 ml. aliquots and put into Petri dishes, irradiated at 250 kv, 12 mA.
(0-2 copper filtration), at a dose rate of 325 r./min., the source being 130 cm.
from the dishes.
The cumulative survival of the animals in the different groups were studied
and comparisons made between them.
Experiment 2: Comparison of the Effect of Active Immunotherapy by BCG, or
Irradiated Leukaemic Cells or a Combination of these Two Methods, Given After
Grafting the Leukaemia, as Against the Effect of Active Immunotherapy Applied
Before the Graft
(a) Administration ofimmunotherapy 14 days before the graft of the leukaemia
Thirty-seven (C57BL/6 x DBA/2)F1 mice were given 104 L1210 leukaemic
cells subcutaneously. Fourteen days previously, they hadbeendivided, atrandom
into 4 groups: the first (11 animals) acted as controls and were not treated; the
second (10 animals) had been given 1 mg. of BCG intravenously, which was then
repeated every fourth day, beginning on the 14th day before the graft. The third
group (6 animals) had been treated on the 14th day before the graft by a single
subcutaneous injection of 107 leukaemic cells that had been irradiated with
15,000 rads, as described above. The fourth group (10 animals) has been given a
combination of both these treatments.
The tumour volume was measured every second day and the date ofdeath was
recorded and a cumulative survival curve constructed for these animals.
(b) The administration ofimmunotherapy, 24 hours, 4 days or 6 days, after the graft
ofthe leukaemia
These experiments only differed from the preceding ones by the dates of
injection of the irradiated leukaemic cells or the first injection of BCG being
made on the 24th hour, or the fourth or sixth day before the graft ofthe leukaemia.
In the first sub-group, receiving immunotherapy 24 hours after the graft of
the leukaemia, 10 animals received BCG alone, 9 received irradiated leukaemic
cells, and 9 a combination of these two treatments. In a second sub-group,
given immunotherapy 4 days after the graft of the leukaemia, 8 animals received
BCG alone, 9 irradiated cells, and 9 a combination of these two treatments. In
a third sub-group, which received immunotherapy on the 6th day after the graft
11 animals received BCG alone, 9 irradiated cells and 8 a combination of these
two treatments.
* From the Institut Pasteur, Paris, France.
t From the Laboratoire Joly, 95-Eaubonne, France.
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Experiment 3: Effect of Active Immunotherapy Applied after the Graft of the
Leukaemia, According to the Number of Leukaemic Cells that were Grafted
Five hundred and twenty-three (C57BL/6 x DBA/2)F1 female mice were used
for this experiment. They were divided into 6 groups at random and were injected
subcutaneously with various numbers of L1210 leukaemic cells: 88 mice in group
I received 10 cells; 90 mice in group II received 106; 90 mice in group III received
105; 84 mice in group IV received 104; 86 mice in group V received 103 and 85 mice
in group VI received 102 leukaemic cells.
The animals in each of these groups were then subdivided into 4 groups,
A, B, C and D. The animals in group A acted as controls. The animals in
group B received, during the 24 hours which followed the graft of the L1210
leukaemia, an intravenous injection of 1 mg. of BCG; this injection was repeated
every fourth day for 30 days. The animals in group C received, during the first
24 hours which followed the tumour graft, a single subcutaneous injection of
107 L1210 leukaemic cells previously irradiated in vitro with a dose of 15,000 rads
as described above. The mice in group D were treated by both the BCG and the
irradiated leukaemic cells.
RESULTS
Experiment 1: Comparison of the Effect, on Leukaemia Produced by the Injection
of i04 Cells, of a Single or Repeated Injection of Various Adjuvants, or Irradiated
Leukaemic Cells Given After the Graft of the Leulkaemia
It can be seen, in Fig. 1, that among the adjuvants or substances used for their
possible adjuvant properties, only BCG, when given repeatedly, showed any
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FIG. 1.-Cumulative survival of mice carrying L1210 leukaemia, not treated or treated by
adjuvants (one injection or several injections) or irradiated leukaemic cells (one injection
or several injections).
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appreciable result. This treatment resulted in a certain number of the animals
eliminating the grafted cells. On the 40th day of the experiment, the difference
in mortality between the animals treatedwith BCG and the controls was significant
(P < 1 per cent).
It can be seen also that the mortality of the mice can be increased by the
administration of certain adjuvants, particularly Bordetella perussis. This seems
to be mainly due to toxicity rather than immunological enhancement for, in none
oftheexperiments was thetumour volume ofthe animals treatedwiththeadjuvant
greater than that in the control animals. This slight increase of early mortality
was also seen in these experiments after the repeated injections of BCG. This
effect on the early deaths was not present in all the experiments, as will be shown
later.
In Fig. 1, it can be seen that the effect of irradiated leukaemic cells is better
than that of BCG, which was the best of the adjuvants tried in this experiment,
and that the effect of repeated injections of the irradiated leukaemic cells was
not significantly better than that of a single injection.
Experiment 2: The Effect ofActive Immunotherapy by BCG, or Irradiated Leukaemic
Cells or a Combination of these Two, Applied After Giving the Leukaemic Graft, as
Compared to the Effects of Active Immunotherapy Applied Before the Graft
This experiment, using 104 grafted leukaemic cells as before, shows first the
difference of action according to the date of giving the BCG and the irradiated
leukaemic cells. The BCG was very effective when it was given 14 days before
the tumour graft (the difference between the controls is very significant: P < 0* 1),
whilst the leukaemic cells had hardly any effect (no effect upon the tumour volume
and a non-significant prolongation of survival) (Fig. 2).
The irradiated leukaemic cells were very effective when they weregiven 24hours
after the tumour graft, the difference from the controls is very significant (P < 0* 1),
whilst the BCG was hardly effective (no effect upon the tumour volume and a
non-significant prolongation ofthe survival) (Fig. 3).
The irradiated tumour cells were still effective in prolonging survival when they
were given 4 days after the graft of the leukaemia (P < 5 per cent) (Fig. 4).
On the sixth day, no effect could be detected either on the mean survival time
or on the tumour volume (Fig. 5).
This experiment also shows that the effect of the combination of BCG and
irradiated leukaemic cells is better than that ofBCG, even when it is given 14 days
before the graft ofthe leukaemia (a significant difference ofP < 1 per cent on the
40th day), or than that of irradiated leukaemic cells, even when they were given
24 hours after the graft, or 4 days after the graft of the leukaemia (a significant
difference of P < 1 per cent on the 30th day). There is an addition or possible
potentiation of these two immunotherapeutic effects.
Experiment 3: The Effect of Active Immunotherapy Applied After the Graft of the
Leukaemia, According to the Number of Tumour Cells Injected
Fig. 6 shows the cumulative survival curves of the animals, according to the
number oftumour cells with which they were grafted. It will be seen that 100 per
cent mortality was only obtained in controls for animals receiving more than
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FIG. 2.-Tumour volume and cumulative survival of mice grafted with L1210 leukaemia and
not treated, or treated by BCG (first injection 14 days before the graft and injections repeated
every fourth day) or irradiated leukaemic cells (one injection 14 days before the graft), or
association ofboth.
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FiG. 3.-Tumour volume and cumulative survival of mice grafted with L1210 leukaemia and
not treated or treated by BCG (first injection 24 hours after the graft and injections repeated
each 4 days), or irradiated leukaemic cells (one injection 24 hours after the graft), or associa-
tion ofboth.
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FIG. 4.-Tumour volume and cumulative survival of mice grafted with L1210 leukaemia and
not treated, or treated by BCG (first injection 4 days after the graft and injections repeated
each 4 days), or irradiated leukaemic cells (one injection 4 days after the graft), or association
ofboth.
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FIG. 5.-Tumour volume and cumulative survival of mice grafted with L1210 leukaemia and
not treated, or treated by BCG (first injection 6 days after the graft and injections repeated
each 4 days), or irradiated leukaemic cells (one injection 6 days after the graft), or association
ofboth.
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FiG. 6. Cumulative survival of mice grafted with 102 to 107 L1210 leukaemia cells: not
treated or treated in the 24 hours following the graft by BCG (repeated injection) or irradiated
leukaemic cells (one injection), or association of BCG and leukaemic cells.
103 leukaemic cells; the animals who only received 102 cells did not have greater
than 60 per cent mortality.
None of the three treatments was effective in the animals that received 107 or
106 leukaemic cells; on the other hand, BCG and the vaccination with irradiated
tumour cells and the combination of these two treatments gave only an increase
of the mean survival time and a cure of a certain number of the animals in the
4 groups of mice which had received 105 leukaemic cells or less.
Table I shows a resume ofthese results and a statistical analysis.
TABLE I.-Experiment 3. Statistical Analysis of the Difference ofSurvival
of Treated Group of Animals Compared to the Controls (P Values)
Number of Leukaemic cells grafted
to induce the Leukaemias 107 106 105 104 103 102
BCG . . . . . . 0 . 0 . 0.1 0-1. 0.1 0-1
Irradiated leukaemic cells . 0 . 0 . 0.1 . 0.1 . 0*1 . 0*1
BCG+Irradiatedleukaemic cells . 0 . 0 . -1 . 0-1 . 0-1 . NS
This experiment also shows that the combination of repeated BCG and the
administration ofa single injection ofirradiated leukaemic cells was more effective
against the leukaemia than the administration of BCG alone, or of irradiated
leukaemic cells, when the number of grafted leukaemic cells was 105. This
difference was very significant at the 30th day: P < 1 per cent.
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DISCUSSION
It has been shown that the administration, before the graft of a tumour, of
adjuvants (Amiel, 1967; Biozzi et al., 1959; Old, Clarke and Benacerraf, 1959)
or of inactivated tumour cells (Glynn et al., 1963), can inhibit the growth of the
tumour. Active immunotherapy was only conceived as a method of preventive
therapy, such as in the case ofinfectious diseases. But preventive active immuno-
therapy is outside any therapeutic, clinical application, because of the ignorance
of tumour antigens in human cancers.
The experiments reported in this work demonstrate the possible curative
action of active immunotherapy against an established experimental tumour.
The L1210 leukaemia was grafted into F1 hybrid animals and makes it likely
that allogeneic inhibition effects (Moller, 1964) were probably associated with the
inhibition caused by the immunisation. Choquet and Malaise (unpublished data),
working in this laboratory, have shown that allogeneic inhibition is certainly
present when L1210 leukaemic cells are grafted into hybrid (C57BL/6 x DBA/2)F1
mice, but the degree of inhibition is minor in relation to that caused by the
immunisation. The control animals in our experiments enabled us to avoid
attributing to immunisation any effect that may have arisen from allogeneic
inhibition.
L1210 leukaemia is a leukaemia which has passed hosts by successive grafting
and it can be questioned whether the leukaemic cells might have lost their tumour
antigens; a study by Motta (1969) has shown that, though these antigens are
feeble, they are still present in the cells.
Finally, it may be questioned if the immune effects obtained arise from these
tumour antigens or from histocompatibility antigens bound to mutations sustained
either by the leukaemia or by the DBA/2 line which forms part ofthe constitution
of the F1 hybrid. One can reply that, if histocompatibility antigens exist on the
leukaemic cells that are not carried by the recipient mice, they are certainly very
weak, for all grafts ofthis leukaemia kill 100 per cent ofthe recipients when 103 or
more tumour cells are given, and the animals are killed within 11 days once 106 cells
have been injected. Hence, ifhistocompatibility antigens do exist, then they can
only act as very feeble antigens, with a force not greater than that of the tumour
antigens. It is reasonable to hope that the conclusions reached in the present
study can be applied to leukaemias whose only antigenic difference compared to
the host, is due to their tumour antigens.
The first major concept that comes from these experiments is the power of
active immunotherapy to eradicate leukaemia. Fig. 3 shows that 50 per cent
of the mice treated with a combination of BCG and irradiated leukaemic cells
were cured, and Fig. 7, which gives an overall analysis of an experiment and
shows the growth of the tumour volume in each mouse, demonstrates that this
therapy is also able to cause the regression of an established tumour. Though
many chemotherapeutic drugs are capable of delaying the mortality of mice
carrying L1210 leukaemia (Mathe, Schwarzenberg et al., 1968), few are capable of
curing 50 per cent ofthe treated animals, and causing the volume ofan established
tumour to regress, in the manner that was achieved with active immunotherapy
in these experiments.
This power to eradicate leukaemia and to effect a cure, suggests that active
immunotherapy is capable ofdestroying all the cells in a cancer population. This
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FIG. 7.-Tumoral volume of each mouse in a group of mice carrying L1210 leukaemia and
treated by the association of BCG and irradiated leukaemic cells 24 hours after the graft.
is in contrast to chemotherapy, which obeys first-order kinetics (Skipper, Schabel
and Wilcox, 1964).
Two reservations to these concepts should be considered at this point: (a) in
two mice out of 150 animals which survived to the 60th day after a graft ofleuk-
aemia, very late relapses occurred after 120 and 180 days respectively (these
150 animals were in part from the experiments described above, as well as from
other experiments); these two relapses occurred in animals that were thought to
have been cured; (b) though immunotherapy is capable of eradicating an entire
tumour population in a certain percentage ofthe animals that have been treated,
it is only capable of doing this if the population is relatively small. In the case
of L1210 leukaemia in the mouse, only when the number of tumour cells in not
greater than 105. Skipper and his colleagues (1964) have shown that mice carry-
ing L1210 leukaemia, and cured by the administration of cyclophosphamide,
are insensitive to a new graft ofthis leukaemia, owing to an immunisation against
the graft, but this only occurred when the number of tumour cells inoculated
was not greater than 105.
It will be seen that the pattern oftumour growth was according to a Gompertz
function, consisting of two phases, rapid, then slow, and immunotherapy only
acted upon the slow phase: (1) in some instances, immunotherapy reduces the
slope of this part of the growth phase; in this case, it only slightly delays the
mortality; (2) in other animals, the slope ofthis second phase descends, the tumour
regresses and the animal is cured; (3) finally, in other animals, this slope is replaced
by a plateau, associated with a considerable delay ofthe mortality, sometimes to
as long as a month, which is very considerable for L1210 leukaemia: this observa-
tion, as well as the two very late relapses mentioned above, poses the question
whether active immunotherapy may be capable of arresting and maintaining
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cells at Go for a long period; nevertheless, a study in progress, which is based on
the cytophotometric examination of the cells of tumours the growth of which is
represented by a plateau, suggests that, on the contrary, it acts essentially on
the cell loss coefficient, it does not prolong the cycle, and it does not increase
the percentage of cells in Go (L'heritier, Bulens and Speelman, 1969, personal
communication).
From a practical point of view, it is convenient to stress that the repetition of
the administration of BCG, the best of the adjuvants in this study, has a better
curative effect than giving a single dose (but there is a slight increase in the mor-
tality), whilst a single injection of irradiated cells is just as effective as repeated
injections. BCG is more effective than irradiated cells when its administration is
commenced before the graft of the leukaemia. A single injection of irradiated
cells is more effective when given after the graft of the tumour than beforehand.
But, in both these instances, there is another important, practical conclusion:
the combination of BCG and the irradiated leukaemic cells is more effective at
any of the time periods than when these stimuli are given alone (Fig. 2, 3, 4, 5).
This signifies that neither of these two treatments can induce a maximal
stimulatory effect and that it is likely that they act upon two different systems.
This has led us to suggest recommending in clinical practice the use ofthe combina-
tion of an adjuvant with a specific vaccine.
Mathe and his colleagues (Mathe, Amiel et al., 1968; Mathe, et al., 1969) have
recently published the results of a clinical trial in which immunotherapy was used.
The number of leukaemic cells was reduced to a level as low as possible, at first
by chemotherapy to induce a remission, then by complementary chemotherapy,
using sequentially all the drugs that are known to be effective against acute
lymphoblastic leukaemia. The results of this clinical trial, which have been
based upon the results of the experiments discussed in this paper, have been
encouraging. Ten control patients treated by the chemotherapeutic regime and
then receiving no further therapy, all relapsed within 130 days, following the
cessation ofchemotherapy; 12 patients ofthe 20 treated by active immunotherapy,
consisting ofeither the application ofBCG, orvaccinationwithirradiated leukaemic
cells, or a combination of these two treatments, had not relapsed by 130 days.
Seven of these patients have still not relapsed up to the present day: for one of
them, this is more than 31 years; for 2, a period of more than 21 years, and for 4
others, periods of more than 14 years, since stopping chemotherapy.
SUMMARY
(1) In the first experiment, a comparison was made of the effects of BCG,
Corynebacterium parvum, Mycobacterium cheiloni, Bordetella pertussis or irradiated
leukaemic cells, administered once or several times after the graft of 104 L1210
leukaemic cells. Ofthe adjuvants, BCG was the only one with any notable effect,
and repeated administration was more active than when given as a single dose;
the irradiated leukaemic cells were more active than BCG, and had identical
activity whether they were injected once or repeatedly.
(2) In the second experiment, a comparison was made of the effects of BCG,
of irradiated leukaemic cells and a combination of them both, administered at
various times in relation to a graft of 104 L 1210 leukaemic cells. The BCG was
given as repeated doses, whilst the irradiated leukaemic cells were given as a
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single dose. The BCG was more effective than the irradiated leukaemic colls
when they were administered before the graft of the leukaemia; the irradiated
leukaemic cells were more effective when they were given after the graft of the
leukaemia. A combination ofthe two forms ofimmunotherapy was moreeffective
than BCG alone, even when this was administered before the graft oftheleukaemia,
and more active than the irradiated leukaemic cells, even when they were adminis-
tered after the graft of the leukaemia.
(3) In the third experiment, (C57BL/6 x DBA/2)F1 mice were grafted with a
variable number of L1210 (DBA/2) leukaemic cells. They were then treated
during the 24 hours which followed this graft by active immunotherapy, either
non-specific, using BCG, or specific, using leukaemic cells that had been irradiated
at 15,000 rads, or by a combination ofboth. The three procedures were confirmed
not only to be capable of prolonging the survival of the mice but also curing a
considerable number of them. But cure was only obtained in those groups of
animals in which the number of grafted cells was 105 or fewer. When larger
numbers ofleukaemic cells were grafted the treatment was ineffective.
(4) The possible clinical application of these findings is discussed. They have
already been applied to a trial of active immunotherapy for the treatment of
acute lymphoblastic leukaemia in man, and have shown that such a therapy can
be effective.
This work was supported by a grant from I.N.S.E.R.M., No. 66-235.
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